Details for Patent: 8,877,230

Which drugs does patent 8,877,230 protect, and when does it expire?

Patent 8,877,230 protects NATESTO and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 8,877,230

Title:	Controlled release delivery system for nasal applications
Abstract:	This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.
Inventor(s):	Mattern; Claudia (Stans, CH)
Assignee:	Mattern Pharma AG (Vaduz, LI)
Application Number:	13/316,494
Patent Claim Types: see list of patent claims	Use; Delivery; Device; Formulation;

Drugs Protected by US Patent 8,877,230

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014		RX	Yes	Yes						NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Foreign Priority and PCT Information for Patent: 8,877,230

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03025769	Nov 11, 2003

International Family Members for US Patent 8,877,230

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047722
Austria	319426
Australia	2004286781
Brazil	PI0416370
Canada	2541498